Form 4: BioLife Solutions CFO Executes Pre-Planned Stock Sale for Tax Obligations
Insider Transaction Report
BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 877 shares of common stock on July 7, 2025, at $22.27 per share, as part of a pre-arranged 10b5-1 plan to satisfy tax withholding obligations.
Summary
- Troy Wichterman, Chief Financial Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
- The transaction occurred on July 7, 2025.
- A total of 877 shares of common stock were disposed of at a price of $22.27 per share.
- The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted by Mr. Wichterman on January 3, 2023.
- The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
- Following this transaction, Mr. Wichterman beneficially owns 185,808 shares of common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine, pre-planned sale for tax purposes, which is a common occurrence for executives receiving equity compensation and does not indicate a change in company fundamentals or management's view of the company's prospects.
Positives
- The transaction was conducted under a Rule 10b5-1(c) trading plan, indicating a pre-arranged and transparent approach to insider stock sales, which is a positive corporate governance practice.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of January 3, 2023, to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Industry Context
This insider transaction report is specific to BioLife Solutions and its Chief Financial Officer, Troy Wichterman. It does not provide information directly related to broader industry trends or competitive dynamics.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Adherence | The sale was conducted under a Rule 10b5-1(c) trading plan, adopted on January 3, 2023. | 07/07/2025 | This demonstrates adherence to best practices for insider trading compliance, providing transparency and mitigating concerns about trading on non-public information. |
Stakeholder Impact
- Shareholders: The sale of 877 shares by the CFO is a very small percentage of the company's outstanding shares and is for a routine tax obligation, thus having a negligible direct impact on existing shareholders.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 01-03-2023 | Date the Rule 10b5-1(c) trading plan was adopted by Troy Wichterman. |
| 07/07/2025 | Date of the reported stock transaction (sale of common stock). |
| 07/09/2025 | Date the Form 4 filing was signed by Troy Wichterman. |
Keywords
BioLife Solutions, BLFS, Form 4, Insider Transaction, Stock Sale, CFO, Troy Wichterman, 10b5-1 Plan, Tax Withholding, Restricted Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.